title: [Treatment of Paclitaxel-eluting stent restenosis with sirolimus-eluting stent implantation: angiographic and clinical outcomes].
abstract: OBJECTIVE
  The best way to treat drug-eluting stent restenosis remains unclear. The aim of this study was to investigate clinical and angiographic outcomes in patients who presented with paclitaxel-eluting stent restenosis and were treated by sirolimus-eluting stent implantation.
  
  
  METHODS
  The main strategy adopted at our center for the treatment of patients with paclitaxel-eluting stent restenosis was the implantation of sirolimus-eluting stents. This study included all patients treated in this manner, and data were collected prospectively. Routine angiographic follow-up was scheduled at 6-8 months after the intervention. Angiographic restenosis was defined as a restenosis 50% of the diameter in the segment zone. Clinical follow-up was continued for up to 2 years. The major adverse cardiac events monitored were death, myocardial infarction and target lesion revascularization.
  
  
  RESULTS
  The study cohort comprised 43 consecutive patients. At baseline, 33 (76.7%) had focal restenosis, while the remaining 10 (23.3%) had diffuse restenosis. Angiographic follow-up data were available for 36 (83%) patients. Binary restenosis occurred in 6 (16.7%), and instent late luminal loss was 0.32 +/- 0.54 mm. At 2 years, target lesion revascularization had been carried out in 7 (16.3%) patients, while major adverse cardiac events had occurred in 11 (25.8%).
  
  
  CONCLUSIONS
  Implantation of a sirolimus-eluting stent as treatment for paclitaxel-eluting stent failure is a viable therapeutic strategy that was associated in this study with the durable prevention of recurrent restenosis. The 2-year revascularization and major adverse cardiac event rates were high, though they were acceptable for a cohort of such high-risk patients.
authors.affiliation: Deutsches Herzzentrum München y 1 Medizinische Klinik rechts der Isar, Technische Universität, Munich, Germany. byrne@dhm.mhn.de
authors.forename: Robert
authors.initials: R
authors.lastname: Byrne
authors.forename: Raisuke
authors.initials: R
authors.lastname: Iijima
authors.forename: Julinda
authors.initials: J
authors.lastname: Mehilli
authors.forename: Jürgen
authors.initials: J
authors.lastname: Pache
authors.forename: Stefanie
authors.initials: S
authors.lastname: Schulz
authors.forename: Albert
authors.initials: A
authors.lastname: Schömig
authors.forename: Adnan
authors.initials: A
authors.lastname: Kastrati
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use*; D017023:Coronary Angiography; D054855:Drug-Eluting Stents; D005260:Female; D006083:Graft Occlusion, Vascular / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use*; D020123:Sirolimus / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus